Pharmaand Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PHARMAAND
PHARMAAND has one approved drug.
There are nine US patents protecting PHARMAAND drugs.
There are two hundred and fourteen patent family members on PHARMAAND drugs in forty-four countries and thirty-five supplementary protection certificates in twenty countries.
Drugs and US Patents for Pharmaand
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 10,278,974 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,143,241 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,859,562 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pharmaand
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | 6,495,541 | ⤷ Start Trial |
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | 7,351,701 | ⤷ Start Trial |
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | 6,495,541 | ⤷ Start Trial |
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | 7,531,530 | ⤷ Start Trial |
| Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | 7,531,530 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Pharmaand Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1118319 | ⤷ Start Trial |
| Japan | 2016216507 | ⤷ Start Trial |
| Brazil | 112017000865 | ⤷ Start Trial |
| Taiwan | 200530196 | ⤷ Start Trial |
| China | 113209033 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pharmaand Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1633724 | CR 2015 00012 | Denmark | ⤷ Start Trial | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 |
| 1633724 | 2015/016 | Ireland | ⤷ Start Trial | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216 |
| 2534153 | 300958 | Netherlands | ⤷ Start Trial | PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529 |
| 1633724 | 1590019-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218 |
| 2534153 | 48/2018 | Austria | ⤷ Start Trial | PRODUCT NAME: RUCAPARIBCAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 (MITTEILUNG) 20180529 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

